“…Moreover, the substrate of PLC, PIP 2 , also exerts complex effects on TRPC channels, including both some levels of dependence on the presence of PIP 2 for channel activation and also some inhibition by the lipid (Imai et al, 2012;Kim et al, 2008;Lemonnier et al, 2008;Otsuguro et al, 2008;Shi et al, 2012;Thakur et al, 2016). Among these factors, only DAGs have been exploited in drug development to create new analogs that activate TRPC3 channels (Lichtenegger et al, 2018;Tiapko, Bacsa, de la Cruz, Glasnov, & Groschner, 2016). Furthermore, the receptor-operated activation of TRPC4/5 channels also includes G i/o -coupled receptors and the PTX-sensitive G i and G o proteins (Thakur et al, 2016).…”